Glioma Glioblastoma Multiforme
9
5
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
PET-Guided Resection in High-Grade Gliomas
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
WBSI Guided Personalized Delivery of TTFields
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness
Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin
Functional and Ultrasound Guided Resection of Glioblastoma
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )